{"name":"Allakos","slug":"allakos","ticker":"ALLK","exchange":"NASDAQ","domain":"allakos.com","description":"Allakos is a clinical-stage biopharmaceutical company focused on developing treatments for immunology and gastrointestinal (GI) disorders. The company's lead product candidate, AK002, is being investigated for the treatment of eosinophilic gastritis, eosinophilic duodenitis, and eosinophilic esophagitis. Allakos has a strong pipeline of product candidates targeting various GI and immunology indications.","hq":"San Carlos, CA","founded":0,"employees":"N/A","ceo":"Robert Alexander","sector":"Immunology / GI","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":79939000,"netIncome":-115818000,"cash":17753000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"AK002 patent cliff ($0.0B at risk)","drug":"AK002","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"AK001 low dose","genericName":"AK001 low dose","slug":"ak001-low-dose","indication":"Other","status":"phase_2"},{"name":"AK001","genericName":"AK001","slug":"ak001","indication":"Other","status":"phase_1"},{"name":"AK006 IV","genericName":"AK006 IV","slug":"ak006-iv","indication":"Other","status":"phase_1"},{"name":"AK006-SC","genericName":"AK006-SC","slug":"ak006-sc","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AK001 high dose","genericName":"AK001 high dose","slug":"ak001-high-dose","indication":"Eosinophilic gastroenteritis","status":"phase_2"}]}],"pipeline":[{"name":"AK001 high dose","genericName":"AK001 high dose","slug":"ak001-high-dose","phase":"phase_2","mechanism":"AK001 is a bispecific antibody that simultaneously engages Siglec-8 on eosinophils and mast cells while cross-linking them to trigger cell death and reduce type 2 inflammation.","indications":["Eosinophilic gastroenteritis","Eosinophilic colitis","Mast cell activation disorder"],"catalyst":""},{"name":"AK001 low dose","genericName":"AK001 low dose","slug":"ak001-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK001","genericName":"AK001","slug":"ak001","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK006 IV","genericName":"AK006 IV","slug":"ak006-iv","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK006-SC","genericName":"AK006-SC","slug":"ak006-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Allakos Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Allakos reported fourth quarter and full year 2023 financial results, with net loss of $83.4 million and $345.1 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Allakos Announces Collaboration with University of California, San Francisco","summary":"Allakos entered into a collaboration with the University of California, San Francisco to investigate the use of AK002 in treating eosinophilic esophagitis.","drugName":"","sentiment":"positive"},{"date":"2023-09-14","type":"trial","headline":"Allakos Announces Positive Topline Results from Phase 2b Trial of AK002 in Eosinophilic Gastritis","summary":"Allakos announced positive topline results from a Phase 2b trial of AK002 in patients with eosinophilic gastritis.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOdzNqdzZ1REIzbHJWb1h2OTlKQmJudXNGSFk2VHlEY1daRmZfRXR2NkpMSzdLYjJHeENxVFlhOTFPbG1TVGFFOTZ1TDRURGNrNjlqQ2ZRdnpyUkdwZ1ZVZU1LeVJmZ3VDOEg4aU5lV09MVUFmVEpIWFpYeVZySkhqSUlDcWtyOC1yY0J3a21DQ2hNNWEwS2dZaU9oenFBcDJqSUt0T0tPMEpmNWN5aGhBV2JmWGFfeEtWTUpXYVlkMERFQQ?oc=5","date":"2025-09-11","type":"pipeline","source":"TIKR.com","summary":"5 High-Risk, High-Reward Microcap Stocks With Massive Upside Potential and Limited Analyst Coverage - TIKR.com","headline":"5 High-Risk, High-Reward Microcap Stocks With Massive Upside Potential and Limited Analyst Coverage","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSkV1TXBpaUp3UmtVUk8wdzlZQndORFZqck9TalJrSGZDbTY1enBQNW9xNVU5N3MweWF3Tk1WUk45cHJMRkVlaGdkREJnVnJVNEtRWEc0ay1HODVFUFpQWnBiWUwxbHo5ZHUzZ0lPSW9VX0k3Y09aQkJhTnJRaWhaN1RGbkZPdnlrY3BpZHlPUWdscjA2VTlGWTBjVFgwTExVTGxCTWJJRDNoaWc?oc=5","date":"2025-05-15","type":"deal","source":"Investing.com","summary":"Allakos completes merger with Concentra Biosciences - Investing.com","headline":"Allakos completes merger with Concentra Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNdnhZaS1jVUlQVEMwbnFmb0FSQk1kR0pxbzY3NFVWeFY1a0xBZDBmNG5sb2pPR0syU3Z4ZC1WUkN5VzA3dTFqVDhhcjVmVmlyNkNRY3FKWTVpc0pCMEZtVktzWWhGNkZxNmNJMGRhNzhBaFdMXzh4Ull0VDhNOEtwd3Izd2ttU29nMGZKazR3MFBrVkhieGtKRE91QnJKZnR4V1AxejZuWDA1Z3dDMWFGampYN2tpRS16YUNyYVhOeWduMWNNbjlsSUdkbmI4bVA0TGVVek84S3NaRzVYRF9rSUZnbw?oc=5","date":"2025-04-06","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"StockWatch: Biopharma Funds Tumble with Wall Street as Industry Spared from Worst of Tariffs—for Now - Genetic Engineering and Biotechnology News","headline":"StockWatch: Biopharma Funds Tumble with Wall Street as Industry Spared from Worst of Tariffs—for Now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNMzhCVExFbkIxYWxFdUVJQUNXTkZfaE55emk4Zk5iZjdyTTZfandONDZSZ0FWYW5RV2YyX2luWVl5QVRpOFBGMUU5ZnkyT19FdUprNVhjZlpmNXFieWZET2JFckloUzdzMlcyNVVjWkNmSVZ2RXZlc0RhdTBFRkk2S2VaUnVTeUNXbF9ScE8wNVVkTThNNThiRG84aXp5T25HUGU2NFlJaF9QT3Z1QTAtMGdFbTZPWXl0Nmh5QkdjSWlVdw?oc=5","date":"2025-04-02","type":"deal","source":"Fierce Biotech","summary":"Concentra swoops in to buy struggling Allakos, softening the blow of other denied buyout attempts - Fierce Biotech","headline":"Concentra swoops in to buy struggling Allakos, softening the blow of other denied buyout attempts","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-03-27","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're A Bit Worried About Allakos' (NASDAQ:ALLK) Cash Burn Situation - simplywall.st","headline":"Here's Why We're A Bit Worried About Allakos' (NASDAQ:ALLK) Cash Burn Situation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNa1FYM3RfUHBXNjZaNzFqd0NwWUVqcEJVZGhLdUlTaGg5bGY3Y2JQTEpYQjJpbkNzV29teUNBM1h1azZZRk1jLTlpWjlLNVROUzJYODE5Y25mTlVLcVhyTXJ4WEFvakoyT2t5bnNKYV9SSWVNdzFZaFdYN3BPRV9CR1NHei0yaUdU?oc=5","date":"2025-01-28","type":"trial","source":"The Pharma Letter","summary":"Allakos decimated as Phase I Trial of AK006 fails - The Pharma Letter","headline":"Allakos decimated as Phase I Trial of AK006 fails","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPejRBV1ZWMGtxelhUTjljYVJweHRGbk9XTEhaRnIyUV9QU29POFotTUV5cFVoZ1RLMTBpcXRVYmlmNEVva0xEejdPcGtqSHNqOGtLbnJzckFNSk11QmVFR1BTMjVObmY3eTNnazViVVBHMks5UWpvWmdoYmluVXp2clA4OUZza3BCcUdBUFN4R2F0MnB2QjFSN0lmd3YxV1VFci1hYnhOQQ?oc=5","date":"2025-01-28","type":"trial","source":"Clinical Trials Arena","summary":"Allakos cuts 75% of workforce after chronic hives trial failure - Clinical Trials Arena","headline":"Allakos cuts 75% of workforce after chronic hives trial failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQMmI4UXVzeXBvQUhfTEs2N0huYlFYclFlUVU3OHJyVEd1bk0xX3lLTXRfNDEwTm9BaVo2c29wU3J4ZlptakZpZ3JVMlpLSENiYWxUb0ZDX05RU2ZqMEcyNFk2NXR5VzNrNFRITGhDV3NmSmpoVmdJRWNkb3VhM2JXcmx3YzRyMlBfbkE?oc=5","date":"2024-04-09","type":"pipeline","source":"InvestorPlace","summary":"3 Biotech Stocks to Dump Before They Go to Zero - InvestorPlace","headline":"3 Biotech Stocks to Dump Before They Go to Zero","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPajh5TWxmNXhGTkZRN3gzNWVvUDBoRC13Mkd1V1gzLS00V3B4Zk5nNDlFQ2xRVWJrTjBXZUgzWnBoVXZCXzFsTEhMNGxBc0FxUXNib3o2dTdPLWF1WnJ5VDI0eGp2MDZlQll5THpqcE5tMFN4eHN2VnVHT3BIUTJ6clBqR3k5ZEd5eE1ocW1Cb0tzSVRMNTg0TVVKNFc?oc=5","date":"2024-01-16","type":"trial","source":"BioPharma Dive","summary":"Allakos to lay off half of staff, scrap drug after study setback - BioPharma Dive","headline":"Allakos to lay off half of staff, scrap drug after study setback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1XLVNtYmhxNW1yUFByaWV3UkZUeG83bmJ3NVJDa3VzZ2hVdkVkRlE2N25HQmlDYVJGRVFyS0h4dGR3S1ljemxsR2RGYy1KVWpGQmNr?oc=5","date":"2022-09-12","type":"trial","source":"firstwordpharma.com","summary":"Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU) - firstwordpharma.com","headline":"Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE53TnFrRFM1dDkwck5ReFdQZC1SLUxFQ1gzS1FJU3dES1JTUFpHR0l2S1lGVFZ3dmxnTUVWWDB5SXdlMnhOdUZTc0ZTT09wZWZqNXhmYmtkM01Ecm5kelFobEFBUnpUM0FpUzA1QXRLeXB5Q28?oc=5","date":"2022-02-16","type":"pipeline","source":"Barron's","summary":"8 Biotech Stocks So Cheap That Their Technology Is Effectively Free - Barron's","headline":"8 Biotech Stocks So Cheap That Their Technology Is Effectively Free - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE85S0hMVHh6RE5CaFBoX2U1NkRwcnpxMHVxZFlkQUNXelZJc182c2VtRXZCNXNmMHZPcXdhM1BKWndlLXc0Tkd0THd0N2hwQQ?oc=5","date":"2020-09-14","type":"pipeline","source":"Stock Titan","summary":"Latest ALLK News - Allakos Inc. Enters into Agreement to Be Ac... - Stock Titan","headline":"Latest ALLK News - Allakos Inc. Enters into Agreement to Be Ac...","sentiment":"neutral"}],"patents":[{"drugName":"AK002","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":5,"phaseCounts":{"phase_2":2,"phase_1":3},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Gilead Sciences","Incyte Corporation","Pfizer Inc."],"therapeuticFocus":["Immunology","Gastrointestinal (GI) Disorders"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":79939000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-115818000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":17753000,"cashHistory":[],"totalAssets":96601000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}